ZA200901852B - N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same - Google Patents

N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same

Info

Publication number
ZA200901852B
ZA200901852B ZA200901852A ZA200901852A ZA200901852B ZA 200901852 B ZA200901852 B ZA 200901852B ZA 200901852 A ZA200901852 A ZA 200901852A ZA 200901852 A ZA200901852 A ZA 200901852A ZA 200901852 B ZA200901852 B ZA 200901852B
Authority
ZA
South Africa
Prior art keywords
compositions
methods
same
isoindole compounds
methylaminomethyl
Prior art date
Application number
ZA200901852A
Other languages
English (en)
Inventor
George W Muller
Roger S C Chen
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of ZA200901852B publication Critical patent/ZA200901852B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
ZA200901852A 2006-09-15 2007-09-14 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same ZA200901852B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84522706P 2006-09-15 2006-09-15

Publications (1)

Publication Number Publication Date
ZA200901852B true ZA200901852B (en) 2010-06-30

Family

ID=38983295

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200901852A ZA200901852B (en) 2006-09-15 2007-09-14 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same

Country Status (30)

Country Link
US (2) US8648096B2 (es)
EP (1) EP2076260B1 (es)
JP (1) JP5567339B2 (es)
KR (1) KR20090050107A (es)
CN (2) CN103382197A (es)
AR (1) AR062875A1 (es)
AT (1) ATE502634T1 (es)
CA (1) CA2663376C (es)
CL (1) CL2007002670A1 (es)
CO (1) CO6180446A2 (es)
CR (1) CR10696A (es)
CY (1) CY1112558T1 (es)
DE (1) DE602007013436D1 (es)
DK (1) DK2076260T3 (es)
ES (1) ES2361584T3 (es)
HR (1) HRP20110261T1 (es)
IL (1) IL197566A0 (es)
MX (1) MX2009002666A (es)
NI (1) NI200900031A (es)
NZ (1) NZ575689A (es)
PE (1) PE20080832A1 (es)
PL (1) PL2076260T3 (es)
PT (1) PT2076260E (es)
RS (1) RS51725B (es)
RU (1) RU2009114159A (es)
SI (1) SI2076260T1 (es)
TW (1) TW200819435A (es)
UA (1) UA95975C2 (es)
WO (1) WO2008033567A1 (es)
ZA (1) ZA200901852B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0514865A (pt) * 2004-09-03 2008-06-24 Celgene Corp processo para preparar um composto
ES2402204T3 (es) 2005-06-30 2013-04-29 Celgene Corporation Procedimientos para la preparación de compuestos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona
ES2361584T3 (es) * 2006-09-15 2011-06-20 Celgene Corporation Compuestos de n-metilaminometil-isoindol y composiciones que los comprenden y métodos que usan los mismos.
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
KR101696938B1 (ko) 2008-10-29 2017-01-16 셀진 코포레이션 암의 치료에 사용하기 위한 이소인돌린 화합물
EA201100984A1 (ru) 2008-12-19 2012-01-30 Грэйсуэй Фармасьютикалс, Ллс Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения актинического кератоза
MX336923B (es) 2009-07-13 2016-02-05 Medicis Pharmaceutical Corp Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales.
LT3202460T (lt) 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CA2935495C (en) 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9776972B2 (en) 2013-03-14 2017-10-03 Epizyme Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014153214A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EA030481B1 (ru) 2013-03-14 2018-08-31 Эпизим, Инк. Ингибиторы аргининметилтрансферазы и их применения
US9045455B2 (en) 2013-03-14 2015-06-02 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
CA2941560A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970134B1 (en) 2013-03-14 2018-02-28 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
KR102223060B1 (ko) 2013-04-17 2021-03-05 시그날 파마소티칼 엘엘씨 암 치료를 위한 TOR 키나제 억제제 및 IMiD 화합물을 포함하는 조합요법
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
JP6889101B2 (ja) 2014-08-07 2021-06-18 キャリセラ バイオサイエンシーズ, インコーポレイテッド グルタミナーゼ阻害剤の結晶形態
PL3214081T3 (pl) * 2014-10-30 2021-04-06 Kangpu Biopharmaceuticals, Ltd. Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2017040376A1 (en) * 2015-08-31 2017-03-09 The University Of Toledo Potent phthalate inhibitors of aspartate n-acetyltransferase and selective aspartate pathway inhibitors
CR20180328A (es) 2015-12-15 2018-08-09 Astrazeneca Ab Compuestos de isoindol
EP3440082A1 (en) * 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
US20190255041A1 (en) 2016-10-28 2019-08-22 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating ezh2-mediated cancer
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Cdk4/6媒介性がんを治療するための組成物および方法
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
US11472799B2 (en) 2018-03-06 2022-10-18 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. SPIROCYCLIC COMPOUNDS
CA3096404A1 (en) 2018-04-23 2019-10-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
CA3130469A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
WO2021080936A1 (en) 2019-10-21 2021-04-29 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
WO2021080950A1 (en) * 2019-10-21 2021-04-29 Celgene Corporation Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CN110746400B (zh) * 2019-11-07 2021-12-17 郑州大学 一种靶向雄激素受体的荧光探针及其制备方法
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
DK1064277T3 (da) * 1998-03-16 2005-10-17 Celgene Corp 2-(2,6-dioxopiperidin-3-yl)isoindolinderivater, deres fremstilling og deres anvendelse som inhibitorer af inflammatoriske cytokiner
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
EP1569907B1 (en) * 2002-12-13 2016-03-09 YM BioSciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
ES2402204T3 (es) * 2005-06-30 2013-04-29 Celgene Corporation Procedimientos para la preparación de compuestos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona
ES2361584T3 (es) * 2006-09-15 2011-06-20 Celgene Corporation Compuestos de n-metilaminometil-isoindol y composiciones que los comprenden y métodos que usan los mismos.

Also Published As

Publication number Publication date
UA95975C2 (ru) 2011-09-26
CN101534820A (zh) 2009-09-16
SI2076260T1 (sl) 2011-05-31
WO2008033567A1 (en) 2008-03-20
CO6180446A2 (es) 2010-07-19
DK2076260T3 (da) 2011-06-27
US20140113935A1 (en) 2014-04-24
US20080214615A1 (en) 2008-09-04
CA2663376A1 (en) 2008-03-20
AR062875A1 (es) 2008-12-10
IL197566A0 (en) 2009-12-24
CA2663376C (en) 2015-01-06
TW200819435A (en) 2008-05-01
KR20090050107A (ko) 2009-05-19
CN103382197A (zh) 2013-11-06
CR10696A (es) 2009-05-13
NI200900031A (es) 2010-02-01
ATE502634T1 (de) 2011-04-15
RU2009114159A (ru) 2010-10-20
PE20080832A1 (es) 2008-08-06
DE602007013436D1 (de) 2011-05-05
JP2010503688A (ja) 2010-02-04
EP2076260A1 (en) 2009-07-08
PL2076260T3 (pl) 2011-08-31
EP2076260B1 (en) 2011-03-23
US8648096B2 (en) 2014-02-11
CL2007002670A1 (es) 2008-05-16
ES2361584T3 (es) 2011-06-20
JP5567339B2 (ja) 2014-08-06
CY1112558T1 (el) 2016-02-10
HRP20110261T1 (hr) 2011-05-31
PT2076260E (pt) 2011-06-07
MX2009002666A (es) 2009-04-09
RS51725B (en) 2011-10-31
NZ575689A (en) 2011-12-22

Similar Documents

Publication Publication Date Title
ZA200901852B (en) N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
IL189795A0 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
PT2101766T (pt) Composições e métodos de utilização de (r)-pramipexole
EP1883389A4 (en) LOW IRRITANT COMPOSITIONS AND METHODS OF MAKING SAME
PL2335782T3 (pl) Zastosowanie kompozycji zawierającej HFCO-1233zd
EP2057284A4 (en) COMPOSITIONS AND METHODS FOR MODULATION OF JNK PROTEINS
EP1895838A4 (en) COMPOSITIONS AND METHODS
IL181543A0 (en) Dendrimer based compositions and methods of using the same
ZA200808431B (en) Fungicidal compositions and methods of using the same
IL180907A0 (en) Risedronate compositions and their methods of use
IL191072A0 (en) Therapeutic compositions and methods
EP2067796A4 (en) POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION
PL2101766T3 (pl) Kompozycje i sposoby stosowania (R)-pramipeksolu
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
PL2069467T3 (pl) Kompozycje wydzielające i sposoby stosowania
EP2104554A4 (en) particle compositions
EP2088865A4 (en) METHODS AND COMPOSITIONS AROUND GUGGULPHOSPHOLIPIDS
GB0617171D0 (en) Novel compositions and methods
HK1109576A1 (en) Aequorin-containing compositions and methods of using same
EP2098544A4 (en) POLYMERIZABLE COMPOUNDS AND POLYMERIZABLE COMPOSITIONS
IL186606A0 (en) Compositions and uses of amooranin compounds
GB0412584D0 (en) Composition of matter
GB0501348D0 (en) Compositions and methods
EP2046109A4 (en) PHOTOSYNTHETIC ORGANISMS, COMPOSITIONS AND METHODS FOR GENERATING THESE ORGANISMS
IL195845A0 (en) Methods of making and using rubidium-81-containing compositions